BUSINESS

Hisamitsu to Go Private in Management Buyout Valued at 400 Billion Yen

By Hayate Horiguchi January 8, 2026

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Japanese patch drug powerhouse Hisamitsu Pharmaceutical will go private through a management buyout, under which the company’s top management will acquire all outstanding shares and delist the drug maker from the Tokyo Stock Exchange. Under the transaction, announced late on…

To read the full story

Hisamitsu’s MBO: Is Shareholder Accountability Trust-Building or a Shackle?
February 18, 2026

BUSINESS

Sumitomo Pharma Sees iPSC Therapy as Potential US$1 Billion Global Product
February 18, 2026
AstraZeneca Launches Japan Registry Study of Imfinzi in Limited-Stage SCLC
February 18, 2026
Asahi Kasei Gets Global Rights to Alchemedicine’s Lead Compounds
February 18, 2026
Teijin, ASKA Hook Up on Gynecology Drug Discovery
February 18, 2026
Fycompa Generics Approved despite Extended Patent, Hydrate Switch in Play?
February 17, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Is Calling for an Abolition the Right Play? Rethinking Japan’s FY2027 Off-Year Drug Price Revision

By Ken Yoshino

Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…

COLUMN

AI in Healthcare Hiring: Leveling the Playing Field & Unlocking Human Potential

By Philip Carrigan

The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…